Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05702229 · ClinicalTrials.gov registry record · Phase 2

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2 study of Gastric Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
163
Enrollment target
20
Study locations

NCT05702229 is a Phase 2 study of Gastric Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 163 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05702229, a Phase 2 study of Gastric Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
163 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Conditions Studied

Gastric Cancer

Interventions

  • DRUG Rilvegostomig
  • DRUG AZD0901
  • DRUG Volrustomig
  • DRUG FOLFOX
  • DRUG XELOX

Study Locations (20)

Other

  • Research Site - Beijing
  • Research Site - Hangzhou
  • Research Site - Hangzhou
  • Research Site - Harbin
  • Research Site - Hefei
  • Research Site - Kunming
  • Research Site - Wuhan
  • Research Site - Yinchuan
  • Research Site - Zhengzhou

New York

  • Research Site - New Hyde Park
  • Research Site - New York
  • Research Site - New York
  • Research Site - New York
  • Research Site - Shirley
  • Research Site - The Bronx

California

  • Research Site - Los Angeles
  • Research Site - Los Angeles

Louisiana

  • Research Site - Baton Rouge

Michigan

  • Research Site - Grand Rapids

Pennsylvania

  • Research Site - Pittsburgh

Trial Details

FieldValue
Enrollment Target 163 participants
Start Date 2023-01-16
Est. Completion 2029-05-31
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05702229

The ClinicalTrials.gov registry entry for NCT05702229 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (49% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Rilvegostomig is the first listed.

NCT05702229 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, New York, California.

Frequently Asked Questions

What is clinical trial NCT05702229 about?

NCT05702229 is a clinical study titled "Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma". This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

What is the current status of trial NCT05702229?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2023-01-16. Estimated completion is 2029-05-31.

What conditions does trial NCT05702229 study?

This clinical trial studies the following conditions: Gastric Cancer.

What interventions are being tested in trial NCT05702229?

The interventions under investigation include: Rilvegostomig (DRUG), AZD0901 (DRUG), Volrustomig (DRUG), FOLFOX (DRUG), XELOX (DRUG).

Who is sponsoring clinical trial NCT05702229?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05702229 being conducted?

This trial has 20 study locations across California, Louisiana, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.